0.35
price down icon2.15%   -0.0077
pre-market  プレマーケット:  .34   -0.010   -2.86%
loading
前日終値:
$0.3577
開ける:
$0.36
24時間の取引高:
184.26K
Relative Volume:
1.18
時価総額:
$22.93M
収益:
-
当期純損益:
$-68.80M
株価収益率:
-0.2991
EPS:
-1.17
ネットキャッシュフロー:
$-59.06M
1週間 パフォーマンス:
-5.15%
1か月 パフォーマンス:
-30.15%
6か月 パフォーマンス:
-40.78%
1年 パフォーマンス:
-69.30%
1日の値動き範囲:
Value
$0.332
$0.36
1週間の範囲:
Value
$0.3134
$0.396
52週間の値動き範囲:
Value
$0.30
$1.64

Passage Bio Inc Stock (PASG) Company Profile

Name
名前
Passage Bio Inc
Name
セクター
Healthcare (1153)
Name
電話
(267) 866-0312
Name
住所
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Name
職員
60
Name
Twitter
@passage_bio
Name
次回の収益日
2025-03-04
Name
最新のSEC提出書
Name
PASG's Discussions on Twitter

PASG を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PASG
Passage Bio Inc
0.35 22.93M 0 -68.80M -59.06M -1.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Passage Bio Inc Stock (PASG) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-29 再開されました Wedbush Outperform
2024-09-03 開始されました Rodman & Renshaw Buy
2022-03-08 ダウングレード JP Morgan Overweight → Neutral
2022-01-19 ダウングレード Goldman Buy → Neutral
2021-07-01 開始されました Raymond James Outperform
2021-06-15 開始されました BTIG Research Buy
2021-03-04 アップグレード Goldman Neutral → Buy
2021-02-04 開始されました Guggenheim Buy
2021-01-25 開始されました Wedbush Outperform
2021-01-04 アップグレード JP Morgan Neutral → Overweight
2020-12-11 開始されました Citigroup Neutral
2020-08-14 ダウングレード JP Morgan Overweight → Neutral
2020-06-25 ダウングレード Goldman Buy → Neutral
2020-03-25 開始されました Chardan Capital Markets Buy
2020-03-24 開始されました Cowen Outperform
2020-03-24 開始されました Goldman Buy
2020-03-24 開始されました JP Morgan Overweight
すべてを表示

Passage Bio Inc (PASG) 最新ニュース

pulisher
Apr 17, 2025

Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia

Apr 17, 2025
pulisher
Apr 17, 2025

Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 15, 2025

Fierce Biotech Layoff Tracker 2025: Mural lays off 90%; Pfizer sells site, cuts staff - Fierce Biotech

Apr 15, 2025
pulisher
Apr 09, 2025

Analyzing Agenus (NASDAQ:AGEN) & Passage Bio (NASDAQ:PASG) - Defense World

Apr 09, 2025
pulisher
Apr 07, 2025

PASG stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia

Apr 07, 2025
pulisher
Apr 03, 2025

Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com

Apr 03, 2025
pulisher
Apr 03, 2025

GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com

Apr 03, 2025
pulisher
Mar 31, 2025

Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Passage Bio stock plunges to 52-week low of $0.35 - Investing.com

Mar 31, 2025
pulisher
Mar 28, 2025

Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace

Mar 28, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com

Mar 27, 2025
pulisher
Mar 25, 2025

Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech

Mar 25, 2025
pulisher
Mar 23, 2025

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo

Mar 23, 2025
pulisher
Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025
pulisher
Mar 16, 2025

Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo

Mar 16, 2025
pulisher
Mar 13, 2025

Passage Bio stock plunges to 52-week low of $0.38 amid market challenges - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Passage Bio stock plunges to 52-week low of $0.38 amid market challenges By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MyChesCo

Mar 13, 2025
pulisher
Mar 09, 2025

Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program - MSN

Mar 09, 2025
pulisher
Mar 08, 2025

Wedbush Comments on Passage Bio’s Q1 Earnings (NASDAQ:PASG) - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know - Nasdaq

Mar 07, 2025
pulisher
Mar 07, 2025

FY2029 Earnings Forecast for Passage Bio Issued By Wedbush - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating -March 05, 2025 at 07:36 am EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Passage Bio (NASDAQ:PASG) Price Target Lowered to $6.00 at Chardan Capital - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Passage Bio Advances Gene Therapy for Neurodegenerative Diseases - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Strategic Restructuring and Promising Data Catalysts Drive Buy Rating for Passage Bio - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Chardan cuts Passage Bio stock price target to $6, maintains buy - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Chardan cuts Passage Bio stock price target to $6, maintains buy By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Passage Bio stock plunges to 52-week low of $0.45 - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Passage Bio stock plunges to 52-week low of $0.45 By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Passage Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.

Mar 04, 2025
pulisher
Mar 04, 2025

PASSAGE BIO, INC. Full Year Loss Decreases - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

Passage Bio Reports 2024 Financial Results and Program Advances - TipRanks

Mar 04, 2025

Passage Bio Inc (PASG) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
大文字化:     |  ボリューム (24 時間):